Gaudium Ivf And Women Health Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Gaudium IVF and Women Health Ltd is ₹ 92.3 as of 23 Oct 15:30 . The P/E Ratio of Gaudium IVF and Women Health Ltd changed from 21.2 on March 2026 to 21.2 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Gaudium IVF and Women Health Ltd changed from ₹ 519.04 crore on March 2026 to ₹ 519.04 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Gaudium IVF and Women Health Ltd for the Jun '26 is ₹ 20.5 crore as compare to the Mar '26 revenue of ₹ 30.53 crore. This represent the decline of -32.85% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Gaudium IVF and Women Health Ltd for the Jun '26 is ₹ 3.55 crore as compare to the Mar '26 ebitda of ₹ 12.35 crore. This represent the decline of -71.26% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Gaudium IVF and Women Health Ltd changed from ₹ 3.4 crore to ₹ 1.78 crore over 7 quarters. This represents a CAGR of -30.91% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Gaudium IVF and Women Health Ltd changed from 47.88 % on March 2023 to 0 % on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Gaudium IVF and Women Health Ltd

Gaudium IVF and Women Health Limited was originally incorporated in the name of 'Gaudium IVF and Women Health Private Limited' as a Private Limited Company, dated March 24, 2015 with the RoC, Delhi and Haryana.
Subsequently, the status of the Company was converted from a Private Limited into a Public Limited and the name was changed to Gaudium IVF and Women Health Limited', and a fresh Certificate of Incorporation dated October 24, 2024 was issued by the Central Processing Center. Company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years.
Gaudium IVF is founded by the Promoter Dr. Manika Khanna, a specialist with advanced training in gynecological endoscopic surgery from Kiel, Germany, and in Gynaec Endoscopy from Melbourne IVF Gujarat Private Limited.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Gaudium IVF and Women Health Ltd and Syngene International Ltd

Which company has a larger market capitalization, Gaudium IVF and Women Health Ltd or Syngene International Ltd?

Market cap of Gaudium IVF and Women Health Ltd is 671 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Gaudium IVF and Women Health Ltd and Syngene International Ltd?

The stock performance of Gaudium IVF and Women Health Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gaudium IVF and Women Health Ltd and Syngene International Ltd?

As of October 25, 2026, the Gaudium IVF and Women Health Ltd stock price is INR ₹92.3. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Gaudium IVF and Women Health Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Gaudium IVF and Women Health Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.